Circulating glucocorticoid levels oscillate with a robust circadian rhythm, yet the physiological relevance of this rhythmicity remains unclear. Here, we show that modulation of circadian glucocorticoid oscillation by enhancing its amplitude leads to anxiolytic-like behavior. We observed that mice with adrenal subcapsular cell hyperplasia (SCH), a common histological change in the adrenals, are less anxious than mice without SCH. This behavioral change was found to be dependent on the higher amplitude of glucocorticoid oscillation, although the total glucocorticoid secretion is not increased in these mice. Genetic and pharmacologic experiments demonstrated that intermediate opioid peptides secreted from SCH activate CXCR7, a b-arrestinbiased G-protein-coupled receptor (GPCR), to augment circadian oscillation of glucocorticoid levels in a paracrine manner. Furthermore, recapitulating this paracrine axis by subcutaneous administration of a synthetic CXCR7 ligand is sufficient to induce anxiolytic-like behavior. Adrenocortical b-arrestinbiased GPCR signaling is a potential target for modulating circadian glucocorticoid oscillation and emotional behavior.
INTRODUCTION
Glucocorticoids, vital stress hormones released as the end products of the hypothalamic-pituitary-adrenal (HPA) axis, affect emotional behavior by directly acting on numerous brain regions (Holsboer and Ising, 2010; McEwen, 2007) . When exposed to stress, the adrenal glands secrete glucocorticoids through the activation of the HPA axis. Glucocorticoids subsequently send feedback to the brain and suppress the stress response. A dysregulated HPA axis with aberrant glucocorticoid signaling in the brain is often observed in patients with stress-related disorders, including anxiety, depression, and posttraumatic stress disorder (de Kloet et al., 2005) . Likewise, functionally relevant polymorphisms of the glucocorticoid receptor gene are associated with susceptibility to major depression (van Rossum et al., 2006) .
In the absence of stressors, the HPA axis is regulated by the master pacemaker located in the suprachiasmatic nucleus (SCN) (Chung et al., 2011; Dickmeis, 2009) . Therefore, circulating glucocorticoid levels oscillate with a robust circadian rhythm. The circadian timing system allows organisms to align their internal behavioral and metabolic processes with the external lightdark cycle (Bass, 2012; Bass and Takahashi, 2010) . Disruption of this circadian alignment can lead to emotional disorders (Keers et al., 2012; Mansour et al., 2005; Roybal et al., 2007) . Conversely, improvement of circadian abnormalities is likely to be beneficial for the control of emotional stability (Boivin, 2000; Bunney and Bunney, 2000) . In order to translate circadian time information into physiologically relevant signals, the master pacemaker in the SCN synchronizes both subordinate extra-SCN oscillators in the brain and subordinate oscillators in peripheral systems through hormonal and neuronal pathways (Bass and Takahashi, 2010) . The rhythmic secretion of glucocorticoids and their ability to reset circadian time in peripheral tissues suggest that glucocorticoid signaling acts as one of the time cues (zeitgebers) required to entrain subordinate oscillators (Balsalobre et al., 2000; Le Minh et al., 2001; Oishi et al., 2005) . Given the pharmacological effects of glucocorticoids in the brain and their possible roles as a zeitgeber, it is intriguing to hypothesize that rhythmic glucocorticoid signaling organizes temporal gene expression profiles across different brain regions, thereby coordinating higher brain functions. Indeed, circadian expression of the rate-limiting serotonin-producing enzyme tryptophan hydroxylase-2 in the dorsal raphe nucleus is totally dependent on circadian glucocorticoid oscillation (Malek et al., 2007) . Thus, modulation of circadian glucocorticoid oscillation by changing its period, phase, or amplitude may affect emotional behavior. Notably, approximately one-half of patients with depression have been reported to display disturbed circadian glucocorticoid oscillation such as dampened circadian amplitude with elevated nadir (Keller et al., 2006; Yehuda et al., 1996) . However, the physiological significance of circadian glucocorticoid oscillation in the regulation of emotional behavior is not fully understood. Possibly this is because no pharmacological tool exists to manipulate circadian glucocorticoid oscillation specifically.
Glucocorticoid secretion and behavior can be modulated by histological changes in the adrenal glands. This is supported by the fact that pathological lesions in the adrenal cortex, such as glucocorticoid-producing tumors and dysplasia, cause adrenocorticotropic hormone (ACTH)-independent Cushing syndrome. Patients with Cushing syndrome exhibit psychiatric disturbances due to chronic glucocorticoid excess with a suppressed HPA axis (Wolkowitz et al., 2009) . The adrenal gland is a highly plastic tissue that remodels with age (Bland et al., 2003) . Development of subcapsular cell hyperplasia (SCH), a common histological change distinct from tumors and dysplasia, is known as one of the characteristics of adrenal tissue remodeling in rodents and humans (Aiba and Fujibayashi, 2011; Kim et al., 2005; Kovatch et al., 1986; Yoshida et al., 1986) . In this report, we describe the unexpected effects of adrenal SCH on circulating glucocorticoid levels and anxiety-like behaviors. By identifying biological functions of SCH and analyzing the underlying mechanisms, we have been able to demonstrate that circadian oscillation of glucocorticoid levels is involved in the regulation of emotional behavior and, furthermore, that circadian glucocorticoid oscillation can be modulated via a b-arrestin-biased G-protein-coupled receptor (GPCR) in the adrenal glands. 
RESULTS

Subcapsular Cell Hyperplasia in the Adrenal Cortex Expresses
Proenkephalin A mRNA in Mice While we were studying the expression of neuropeptide precursor genes in the adrenal medulla, a neuropeptide-rich tissue, we unexpectedly found that adrenal SCH cells express Proenkephalin A mRNA ( Figures 1A and 1B) . SCH is a common physiological change, which starts to appear around 4 months of age and develops gradually thereafter (Yoshida et al., 1986) . Consistent with this notion, Proenkephalin A in SCH appeared after 4 months in male mice, whereas the first appearance occurred at about 6 months in females. As previously reported, the adrenal medulla also expresses Proenkephalin A mRNA at 2 months of age in both sexes ( Figure 1A ) (Jingami et al., 1984) . The peptide precursor proenkephalin A is cleaved by prohormone convertases, such as furin and PCSK2, to produce various opioid peptides, peptide fragments containing the classical opioid motif (YGGFM [Met-enkephalin; MetEnk] or YGGFL [LeuEnk] ) at the N terminus ( Figure 1C ) (Dillen et al., 1993) . Previous studies have demonstrated that furin cleaves proenkephalin A partially into intermediate fragments, whereas PCSK2 processes proenkephalin A fully to produce mature MetEnk and LeuEnk (Breslin et al., 1993) . Brains from PCSK2 knockout mice were markedly depleted of mature enkephalins (Johanning et al., 1998) . To assess whether intermediate peptide fragments are produced in mouse adrenal glands, where Furin, but not Pcsk2, is expressed ( Figure 1A ), we analyzed tissue peptide extracts by reverse-phase high-performance liquid chromatography (HPLC) followed by a LeuEnk ELISA that cross-reacts with intermediate peptides containing a C-terminal LeuEnk sequence. Indeed, we found that the adrenal gland produces intermediate proenkephalin A-derived fragments, such as peptide E and peptide I ( Figure 1C and Figure S1 available online).
The adrenal cortex receives its blood supply from small arteries that form an arteriolar plexus lying within and below the capsule. The arteriolar plexus then gives rise to a dense sinusoidal network that runs through the cortex to the medulla ( Figure 1B) . Thus, molecules secreted from SCH can be conveyed centripetally and act on adrenocortical cells. This anatomy of portal circulation and Proenkephalin A expression in SCH cells prompted us to test whether the presence of SCH modulates glucocorticoid secretion in vivo.
SCH Enhances Circadian Glucocorticoid Oscillation in a
Proenkephalin A-Dependent Manner Since considerable variations in SCH development are observed among individual mice, SCH was evaluated histologically in all mice at the end of experiments. Mice were then grouped retrospectively based on the presence and absence of SCH. First, we studied if SCH affects acute stress-induced glucocorticoid secretion. Mice were subjected to 30 min of restraint stress, and plasma corticosterone levels were measured at different time points. Corticosterone levels increased significantly after restraint stress and returned toward basal levels at 120 min both in the presence and absence of SCH ( Figure 2A ). Second, we performed a dexamethasone suppression test (DST), a measure of negative-feedback inhibition of the HPA axis. In response to dexamethasone challenge, corticosterone release was equally suppressed in both groups ( Figure 2B ). These results suggest that mice with SCH maintain a functional HPA axis. Under basal conditions without stressors, plasma corticosterone levels oscillate with a robust circadian rhythm. We confirmed an intact circadian corticosterone rhythm with a similar period and phase both in the presence and absence of SCH ( Figures 2C and 2D) . Interestingly, however, we found that circadian peak levels of corticosterone measured at ZT12 were higher in female mice with SCH as compared to individuals without this hyperplasia, whereas there was no difference at other time points ( Figure 2D ). Consistent with this finding, the overall levels of corticosterone were not altered in female mice with SCH (two-way ANOVA, P SCH > 0.05), but the amplitude of circadian corticosterone oscillation was significantly higher in the presence of SCH (Figures 2D and 2E) . Notably, no difference was observed in males across the day ( Figure 2C ).
Circulating ACTH secreted from the pituitary gland is a major physiological regulator of glucocorticoid production in vivo. No difference was noted in plasma ACTH levels in the presence of SCH in females ( Figure 2F ), supporting our hypothesis that molecules secreted from SCH cells modulate corticosterone production by acting on adrenocortical cells in a paracrine manner. Other physiological measures such as body weight and serum biochemical parameters were also found to be unaffected in the presence of SCH (Table S1) .
Next, we examined whether this endocrinological effect of SCH is mediated by Proenkephalin A gene expressed in SCH. In contrast to wild-type (WT) female mice, the effects of SCH were not observed in female Proenkephalin A knockout (Penk À/À ) mice ( Figure 2G ). These data indicate that SCH enhances circadian glucocorticoid oscillation in a Proenkephalin A-dependent manner in females.
SCH Induces Anxiolytic-like Behavior by Enhancing Circadian Glucocorticoid Oscillation
Neural circuits underlying emotional behavior are highly sensitive to alterations in plasma glucocorticoid levels (de Kloet et al., 2005) . Having observed the enhanced glucocorticoid oscillation with a normal HPA axis in the presence of SCH, we studied whether this endocrinological change affects emotional behavior. All behavioral tests were performed at the beginning of the activity phase. First, general locomotor activity was measured in the open field test. There was no difference in the novel environment-induced locomotion in the presence of SCH ( Figure 3A) . Importantly, however, female mice with SCH stayed longer in the central area than females without SCH during the initial 4 min of the session ( Figure 3B ). Anxiolytic-like effects of SCH were further studied in two additional tests assessing anxiety-like behavior. In the elevated plus maze test, female mice with SCH showed a higher percentage of open arm entries and time than females without this hyperplasia ( Figure 3C ), although the absolute number of entries into all arms was not different between the two groups ( Figure S2A ). To examine whether this behavioral change is dependent on the altered glucocorticoid secretion induced by SCH, mice were treated with a glucocorticoid receptor antagonist. We chose a dose that does not activate basal HPA axis activity ( Figure S2B ). Under this low-dose antagonist treatment (RU486; 20 mg/kg, injected intraperitoneally 6 hr before circadian peak of glucocorticoid secretion for 4 days), the anxiolytic-like effects of SCH were totally abolished ( Figure 3D ). Concordant with this result, SCH did not elicit anxiolytic-like behavior in males, which exhibit no difference in circadian glucocorticoid oscillation (Figures 2C, 3B, and 3E). These results indicate that SCH induces anxiolytic-like behavior by enhancing circadian glucocorticoid oscillation. Glucocorticoid-dependent anxiolytic-like effects of SCH were also observed in the light-dark box test (Figures 3F and S2C) . Since the enhanced glucocorticoid oscillation is dependent on Proenkephalin A gene expressed in SCH, we performed behavioral tests using female Penk À/À mice. As expected, anxiolytic-like effects of SCH were not observed in female Penk À/À mice ( Figure S2D ). We also studied the effects of SCH on depression-like behavior in the forced swim test. No difference was noted in this paradigm ( Figure S2E ). Since advancing the phase of the sleep/wake cycle can exert an antidepressant effect (Bunney and Bunney, 2000) , we assessed the effects of SCH on the sleep/wake rhythms by recording polysomnography (electroencephalogram [EEG] and electromyogram [EMG] ) in female mice. No overt difference was observed in the phase or amplitude of sleep/wake rhythms ( Figure S2F ). Interestingly, however, total awake time was shorter in mice with SCH (Table S2) . cells: ATCC.CRL-2128) as a model system. This led to the discovery that BAM22 augments ACTH-induced glucocorticoid secretion in a dose-dependent manner ( Figure 4A ). Peptide E, another BAM22-related peptide, was also found to have comparable activity ( Figure S3A ). These results coincide with our hypothesis that SCH cells produce partially processed opioid peptides ( Figures 1A, 1C , and S1). BAM22 and peptide E contain the MetEnk sequence at the N terminus ( Figure S3B ). Thus, BAM22 is able to activate the canonical G-protein-coupled opioid receptors (d, k, and m) as efficiently as MetEnk, a mature form of enkephalins ( Figure S3C ). Importantly, however, MetEnk did not promote glucocorticoid secretion ( Figure 4A ), suggesting that the effects of BAM22 may be mediated by a receptor distinct from opioid receptors. To further examine this hypothesis, [Phe 1 ]BAM22, a BAM22 mutant that can not activate opioid receptors ( Figure S3C ), was tested. [Phe 1 ]BAM22 and BAM22 equally promoted ACTH-induced glucocorticoid secretion (Fig-(G) Plasma concentrations of corticosterone at ZT0 and ZT12 in 6-month-old Proenkephalin A knockout (Penk À/À ) mice (male: n = 4-9/group; female: n = 7-9/group). The presence of SCH was evaluated histologically by using adrenal sections. Mice were retrospectively grouped based on the presence or absence of SCH. Results are shown as mean ± SEM. *p < 0.05; **p < 0.01. ZT, zeitgeber time. See also Table S1 . (E) Elevated plus maze test. Anxiolytic-like behavior was not observed in males (n = 9/group). (F) Light-dark box test. Glucocorticoid-dependent anxiolytic-like effects of SCH were observed in females (n = 11-16/group). Results are shown as mean ± SEM. *p < 0.05; **p < 0.01. See also Figure S2 and Table S2. ure 4B). Well-conserved amino acid sequences of BAM22 and peptide E also support the idea that they are not only intermediate peptides for mature enkephalins, but they may also have distinct functions per se ( Figure S3B ).
To identify a BAM22 receptor promoting glucocorticoid secretion, we listed and screened all peptidergic GPCRs and peptidergic-like orphan GPCRs expressed in adrenocortical cells. We employed a heterologous b-arrestin-GPCR recruitment assay established in 293T cells for this purpose. This led to the identification of CXCR7 as a receptor for BAM22 ( Figure 4C ). CXCR7 had been identified as a b-arrestin-biased receptor for the chemokines SDF1 and I-TAC (Burns et al., 2006) . Specificity of the interaction was demonstrated by testing proenkephalin A-derived peptide fragments against all known chemokine receptors ( Figure 4D ). Intermediate peptides (BAM22, peptide E, and peptide I), but not mature peptides (MetEnk, LeuEnk, and MetEnkRF), specifically activated CXCR7. Dose-response analyses showed that BAM22, as well as SDF1 and I-TAC, recruit both b-arrestin-1 and b-arrestin-2 at nanomolar concentrations ( Figure 4E ). As predicted from the previous finding that CXCR7 does not activate heterotrimeric G-proteins in response to SDF1 and I-TAC (Rajagopal et al., 2010) , BAM22 elicited neither a cyclic AMP (cAMP) nor a calcium response in H295R cells as well as in 293T cells overexpressing CXCR7 (293T-CXCR7) ( Figures S3D  and S3E ). We then demonstrated direct interaction between ChemR  CCBP2  CCBP1  XCR1  CX3CR1  CCRL2  CCR11  CCR10  CCR9  CCR8  CCR7  CCR6  CCR5  CCR4  CCR3  CCR2  CCR1  CXCR7  CXCR6  CXCR5  CXCR4  CXCR3  CXCR2  CXCR1 Fold Induction of LacZ activity Fold Induction of LacZ activity 0.5 1 1.5 2 2.5 AGTR1  EDNRA  EDNRB  BRS3  GRPR  NMBR  NMUR2  SSTR2  UTS2R  ADCYAP1R1  VIPR1  GLP1R  CXCR7  GPR4  GPR6  GPR15  GPR18  GPR19  GPR21  GPR22  GPR27  GPR35  GPR37  GPR43  GPR63  GPR65  GPR68  GPR84  GPR85  GPR89A  GPR91  GPR132  GPR137B  GPR157  GPR160  GPR170  GPR176  GPR182 12,000 8,000
4,000 Figure 4F ). A structure-activity relationship study was then performed (Table 1) . We tested CXCR7, d opioid receptor (DOR), and MRGPRX1 in parallel, since MRGPRX1 was also reported to be a receptor for proenkephalin A-derived peptides (Lembo et al., 2002) . Among the tested fragments, BAM22 was the most potent ligand for CXCR7 and, conversely, of all the receptors, BAM22 activated CXCR7 most efficiently. Consistent with our data in adrenocortical cells ( Figure 4B) and BAM22 were equally active at CXCR7 in a heterologous b-arrestin-GPCR recruitment assay (Table 1 ; Figure S3F ). Furthermore, the BAM22-CXCR7 interaction was insensitive to naloxone, a classical opioid receptor antagonist ( Figure 4G ). Collectively, these results suggested that CXCR7 and the canonical opioid receptors recognize the structure of BAM22 differently.
CXCR7, the Only Opioid Peptide Receptor Expressed in the Adrenal Cortex, Mediates the Endocrinological Effects of SCH In Vivo
To investigate whether CXCR7 is expressed in the adrenal glucocorticoid-producing cell layer in vivo, we performed in situ hybridization analyses. The expression of Cxcr7 mRNA, but none of the canonical opioid receptors (Oprd1, Oprk1, and Oprm1) or Mrgprx1, was identified in adrenal glands of 6-month-old mice ( Figure 5A ), which is consistent with the previous report that the adrenal gland is one of the most abundant sites of Cxcr7 expression in mice (Regard et al., 2008) . In 6-month-old females, Cxcr7 was strongly expressed in the entire layer of the zona fasciculata, where glucocorticoids are produced. Interestingly, the expression seemed to increase with age. In contrast, a weaker Cxcr7 expression was detected at the junction of the cortex and the medulla in males. These results suggest that, in the adrenal gland, CXCR7 is the only receptor activated by intermediate opioid peptides. Importantly, the sex-dependent adrenocortical expression of Cxcr7 explains why SCH exerts its effects only in females. To examine whether CXCR7 mediates the endocrinological effects of SCH in vivo, we treated mice with intraperitoneal injections of either CXCR7-neutralizing antibody (anti-CXCR7 monoclonal antibody [8F11]; 10 mg/kg) or isotype control immunoglobulin G 2b . In vitro validation of this neutralizing antibody was performed before the experiments ( Figures S4A and S4B ). Under this treatment, the effects of SCH on circadian glucocorticoid secretion were abolished ( Figure 5B ). Together, these results suggest that the effects of SCH are mediated by proenkephalin A-derived peptides acting on CXCR7.
CXCR7-b-Arrestin-MAPK Pathway Mediates the Effects of Intermediate Opioid Peptides in Adrenocortical Cells
Similar to the in vivo histological findings ( Figure 5A ), quantitative PCR analysis demonstrated that adrenocortical cells (H295R) express CXCR7 but none of the canonical opioid receptors or MRGPRX1 ( Figure S4C ; Table S3 ). CXCR7 mRNA was also detected in Y1 cells, another adrenocortical cell line, but its expression levels were considerably lower than those in H295R cells (less than 1%) (data not shown). Knockdown experiments S4D ; Table S3 ). We thus investigated the mechanism by which intermediate opioid peptides promote glucocorticoid secretion utilizing H295R cells as a model system. Through the activation of the melanocortin 2 receptor (MC2R), ACTH elicits G protein-mediated cAMP signaling as well as phosphorylation of p44/p42 mitogen-activated protein kinases (p44/p42 MAPKs, also known as ERK1/2) (Janes et al., 2008) . The latter are known to enhance the steroidogenesis induced by the ACTH-MC2R-cAMP pathway. In contrast to MC2R, CXCR7 is a b-arrestin-biased receptor. b-arrestins function as scaffolds that participate in various signaling pathways, including those of the MAPKs (DeWire et al., 2007) . These considerations suggested a putative mechanistic model in which BAM22-CXCR7-b-arrestin signaling promotes cortisol secretion by enhancing ACTH-induced ERK activation ( Figure 6A ). When either b-arrestin-1 or b-arrestin-2 was knocked down, BAM22 effects were abolished (Figures 5D and S4E ; Table S3 ), indicating that both b-arrestin-1 and b-arrestin-2 are required. This type of codependent regulation has been reported in other receptors as well (DeWire et al., 2007) . The ACTH-induced ERK1/2-phosphorylation was then found to be enhanced and prolonged in the presence of BAM22 ( Figure 5E ). To further examine whether this modulation of ERK1/2 is required for enhanced cortisol secretion, H295R cells were treated with U0126, a selective inhibitor for MEK1/2, upstream activators of ERK1/2. U0126 treatment decreased the basal ACTH-induced cortisol secretion and blocked the stimulatory effects of BAM22 ( Figure 5F ). Collectively, these data support our signaling model ( Figure 6A ).
Activation of CXCR7 Is Sufficient to Induce Anxiolyticlike Behavior
Our results suggest that the opioid-CXCR7-glucocorticoid pathway is a hormonal axis linking adrenal tissue remodeling to anxiolytic-like behavior ( Figure 6A ). Identification of this axis prompted us to test whether activation of CXCR7 by a synthetic ligand is sufficient to induce anxiolytic-like behavior. CCX771 is a small molecule compound with highly specific activity against CXCR7 (Zabel et al., 2009 ). Because of its favorable pharmokinetics, in vivo use of this compound has been well established (Cruz-Orengo et al., 2011) . As previously reported, CCX771 binds to CXCR7 and efficiently recruits b-arrestins (Figures 6B and S5A) (Zabel et al., 2009) . Utilizing cultured adrenocortical cells and isolated adrenal slices, we further confirmed that CCX771 augments glucocorticoid secretion in the presence of ACTH ( Figures 6C, 6D , and S5B). Six-month-old female mice were then treated with CCX771. Subcutaneous twice-a-day injection at a dose of 5 mg/kg for 3 days resulted in increased circulating glucocorticoid levels at ZT12, while no effect was observed at ZT0 ( Figures 6E and 6F ). These endocrinological changes induced by CCX771 treatment were consistent with what we observed in female mice with SCH. Importantly, there was no difference in circulating ACTH levels, eliminating the possibility that CCX771 modulates glucocorticoid secretion by stimulating the upstream components of the HPA axis (Figure S5C) . As predicted from the sex-dependent adrenocortical expression of Cxcr7 ( Figure 5A ), CCX771 exerted no stimulatory effect on glucocorticoid secretion in males ( Figure S5D ). Having observed the increased amplitude of circadian glucocorticoid secretion by CCX771, we then tested its behavioral effects. In the elevated plus maze test, female mice treated with CCX771 displayed anxiolytic-like behavior, which was dependent on glucocorticoid signaling ( Figures 6G and 6H) . These results indicate that the activation of CXCR7 signaling in the glucocorticoidproducing cells is sufficient to induce anxiolytic-like behavior.
DISCUSSION
The peripheral endocrine systems communicate with the brain by secreting hormones, which potentially alter the informationprocessing properties of neural circuits underlying behavior. Overproduction of glucocorticoids from adrenal tumors is known to cause Cushing syndrome. Patients with Cushing syndrome display psychiatric abnormalities including anxiety, depression, and cognitive function deficits (Starkman et al., 1981; Wolkowitz et al., 2009) . Similarly, chronic glucocorticoid administration in mice results in increased anxiety/depression-like behavior (David et al., 2009 ). Pharmacologic strategies aimed at correcting overactivated glucocorticoid signaling, such as glucocorticoid biosynthesis inhibitors and glucocorticoid receptor antagonists, have been utilized for the treatment of Cushing syndrome (Wolkowitz et al., 2009 ). These antiglucocorticoid treatments have also been reported to act synergistically with selective serotonin reuptake inhibitors in depressed patients (Jahn et al., 2004) , indicating that modulation of biological effects of peripherally released hormones has therapeutic potential in neurological and psychiatric disorders. The adrenal glands, the main peripheral source of glucocorticoids, have a remarkable tissue plasticity that allows their remodeling with age (Bland et al., 2003) . SCH, one of the characteristics of adrenal tissue remodeling, is histologically distinct from tumors and dysplasia (Kim et al., 2005; Kovatch et al., 1986; Yoshida et al., 1986) . We have now demonstrated that SCH is functionally different as well. In contrast to adrenocortical tumor cells that secrete steroids, SCH cells secrete intermediate opioid peptides as paracrine hormones. These peptides enhance the circadian oscillation of glucocorticoids without Results are shown as mean ± SEM. *p < 0.05; **p < 0.01. See also Figure S4 and Table S3 . affecting their total daily secretion or HPA axis regulation. The glucocorticoid oscillation is required to maintain circadian activities in certain brain regions (Lamont et al., 2005; Malek et al., 2007) . Likewise, mice designed to have an attenuated circadian glucocorticoid oscillation exhibit altered locomotor activity (Son et al., 2008) . These findings suggest that circadian glucocorticoid oscillation influences behavior. However, the exact physiological relevance of circadian glucocorticoid oscillation in the regulation of emotional behavior has remained unknown. By demonstrating anxiolytic-like effects of SCH, we here provide evidence that enhancing circadian glucocorticoid oscillation, without affecting the HPA axis, is sufficient to alter emotional states. Furthermore, we propose that enhancing the amplitude of glucocorticoid oscillation can be anxiolytic in certain contexts, even though glucocorticoids are generally considered an anxiogenic factor. This is analogous to the previous hypothesis that a marked rise of glucocorticoid levels, accompanied by a return to the basal state, provides an organism with the ability to adapt to stress (Kudielka and Kirschbaum, 2005) . Our results reinforce the idea that circadian glucocorticoid oscillation is involved in higher brain functions regulating emotional behavior.
In this report, we have shown that the Proenkephalin A gene, which encodes one of the peptide precursors that produce endogenous opioid peptides, is expressed in the adrenal SCH. SCH cells secrete intermediate opioid peptides such as BAM22 and peptide E because of the lack of PCSK2, a prohormone convertase required for the full processing to mature enkephalins. BAM22 and peptide E act as endogenous ligands for CXCR7 and exert anxiolytic-like effects by enhancing circadian glucocorticoid oscillation in the adrenal glands. In contrast, neurons mainly produce mature enkephalins, which act as endogenous ligands for DOR in the central nervous system (CNS). Based on genetic evidence that both proenkephalin A and DOR knockout mice display increased anxiety-like behavior (Filliol et al., 2000; Kö nig et al., 1996) , enkephalin-DOR signaling is considered one of the endogenous peptidergic systems that exert anxiolytic-like effects in the CNS. These findings suggest that both intermediate opioid peptides in the adrenal glands and mature enkephalins in the CNS elicit similar behavioral effects, although a totally different ligand-receptor system is involved in each case. We here offer a unifying hypothesis that proenkephalin A gene products exert anxiolytic-like effects in both the CNS and the periphery.
A surprising discovery presented in this report is the identification of CXCR7 as a high-affinity receptor for intermediate opioid peptides, since CXCR7 is known as a receptor for the chemokines SDF1 and I-TAC (Burns et al., 2006; Rajagopal et al., 2010) . The chemokine receptor family is structurally distinct from the canonical opioid receptor family. In agreement with this structural difference, we demonstrate that the complete opioid motif is not required for CXCR7 activation and that CXCR7 acts as a specific receptor for intermediate opioid peptides, but not for mature enkephalins. Furthermore, the BAM22-CXCR7 interaction is distinct from the interaction of BAM22 with canonical opioid receptors in its insensitivity to naloxone. Our results point to a previously unrecognized link between the opioid and chemokine systems and raise the possibility that other peptide precursors may also play unexpected roles by encoding additional ligands.
We have demonstrated that CXCR7 ligands modulate circadian glucocorticoid oscillation by enhancing its amplitude without changing its period or phase. These in vivo results led us to speculate that CXCR7 ligands act synergistically with ACTH. Indeed, in vitro, both endogenous and synthetic CXCR7 ligands do not have any stimulatory effects on glucocorticoid secretion per se but promote glucocorticoid secretion in the presence of ACTH. This stimulatory action of CXCR7 ligands is analogous to the insulinotropic action of glucagon-like peptide-1 (GLP-1), one of the incretins secreted following nutrient ingestion, which stimulates insulin secretion in pancreatic beta cells strictly in a glucose-dependent manner (Marathe et al., 2013) . Interestingly, SCH does not affect the acute stress-induced glucocorticoid synthesis that is partly mediated by the nongenomic effects of ACTH. This suggests that the CXCR7-barrestin-MAPK pathway selectively influences the chronic effects of ACTH by modulating the expression of genes required for basal circadian glucocorticoid production (Arakane et al., 1997; Gallo-Payet and Payet, 2003) . CXCR7 ligand treatments lead to enhanced circadian glucocorticoid oscillation, because their effects are only significant at ZT12. This observation may be explained by recent findings that adrenocortical cells have their own circadian clock machinery, which renders cells more sensitive to extracellular stimuli at the beginning of the activity phase (ZT12) (Oster et al., 2006) . To our knowledge, synthetic CXCR7 ligands are the first pharmacological tool available to manipulate circadian glucocorticoid oscillation in vivo. Although synthetic CXCR7 ligands can modulate neither period nor phase, they offer a simple means of studying physiological and behavioral consequences of changing the circadian amplitude of glucocorticoid oscillation.
Marked sex differences have been reported in adrenal size, circulating glucocorticoid levels, and gene expressions in the adrenal cortex (Bastida et al., 2007; Bielohuby et al., 2007) . We have found that CXCR7 is expressed in the adrenal glucocorticoid-producing cells in a highly sex-dependent manner, which in turn explains the sex differences in the endocrinological and behavioral effects of SCH. Females are reported to have enhanced stress sensitivity and a greater predisposition to stress-related disorders such as depression (Becker et al., 2007 ). An increased occurrence of stress-related disorders after puberty indicates that sex hormones act as powerful modulators of emotional behavior (Kudielka and Kirschbaum, 2005) . However, all sex-related influences on brain function and behavior cannot be explained by the action of sex hormones, since many sex differences are known to persist even without these hormones. Thus, it is evident that sex-related influences on behavior and their underlying mechanisms are enormously diverse (Cahill, 2006) . The sex-dependent effects of SCH support this hypothesis and may add another layer of complexity to this diversity.
In summary, we unexpectedly observed that mice with SCH are less anxious than mice without SCH. SCH cells secrete intermediate opioid peptides as paracrine hormones and they exert anxiolytic-like effects by enhancing circadian glucocorticoid oscillation. Based on our discovery that CXCR7 functions as a receptor for these opioid peptides, we could recapitulate the biological effects of SCH by administering a synthetic CXCR7 ligand. By identifying the biological functions of adrenal SCH, we have shown that modulation of circadian glucocorticoid oscillation by enhancing its amplitude leads to altered emotional states and that b-arrestin signaling in the adrenal glucocorticoidproducing cells is a potential target for affecting glucocorticoid oscillation and emotional behavior.
EXPERIMENTAL PROCEDURES
All animal experiments were performed under protocols approved by the Institutional Animal Care and Use Committee and were strictly in accordance with NIH guidelines. Extended Experimental Procedures are available online.
In Vivo Experiments
For the hormone measurements, blood samples were collected within 30 s of disturbance. Corticosterone and ACTH were measured using commercially available radioimmunoassay and ELISA kits, respectively. After blood collection, both adrenal glands were harvested for histological analysis. Mice with bilateral SCH, which occupies more than one-third of the adrenal circumference, were judged as SCH positive. Samples were grouped based on the presence and absence of the adrenal SCH. For female mice, vaginal smears were performed immediately after each experiment to evaluate the estrus cycle, and similar distributions of the estrus-cycle phases were confirmed between the comparing groups. Dexamethasone 21-phosphate was injected intraperitoneally 6 hr before serum sample collection. Behavioral tests (open field test, elevated plus maze test, light-dark box test, and forced swim test) were performed at ZT12 as previously described (Crawley, 1981; Lister, 1987; Porsolt et al., 1977; Willie et al., 2008) . The glucocorticoid receptor antagonist RU486 (20 mg/kg) was injected intraperitoneally for 4 days at ZT6. Neutralizing antibody against CXCR7 (anti-CXCR7 mAb [8F11]; 10 mg/kg) was injected intraperitoneally and serum samples were collected 96 hr after the injection. CCX771 (kindly provided by ChemoCentryx) was administered subcutaneously twice a day (ZT0 and ZT6) at the dose of 5 mg/kg for 3 days as a solution in 10% Captisol. The endocrinological and behavioral effects of CCX771 were evaluated using mice without SCH.
b-Arrestin-GPCR Recruitment Assay 293T cells were stably transfected with b-arrestin-1/2-u (u: M15 deletion mutant of b-galactosidase) chimera to establish a reporter cell line (293T/ba-M15). 293T/ba-M15 cells were transiently transfected with multiple GPCR-a (a short a peptide fragment of b-galactosidase) chimeras of interest. Cells were stimulated with agonists in OPTI-MEMI/0.1% BSA followed by 90 min of incubation at 37 C. Gal-Screen substrate was added to the wells and the plates were further incubated for 90 min at 25 C. Luminescence was measured in a plate reader (Victor V; Perkin Elmer).
Radioligand Binding Assay 293T cells, stably expressing human CXCR7 (hCXCR7), were harvested in the extraction buffer (50 mM Tris-HCl [pH 7.5], 5 mM MgCl 2 and protease inhibitor cocktail) and 5 mg of membrane fraction was incubated with 0.1 nM of radioligand and various concentrations of unlabeled ligands in the binding buffer (50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 2 mM EDTA, 0.25 M sucrose, and 0.1% BSA). After 90 min incubation at 4 C, the bound ligand was separated from the free ligand by filtering. The amount of the radioligand bound to the receptor was determined by measuring the radioactivity on the filter using a g counter.
Lentivirus-Mediated RNAi
The pLKO-EGFP-IRES-puro vector was generated from pLKO-puro vector (Sigma-Aldrich) with modifications. Small hairpin RNAs (shRNAs) for hCXCR7, hb-arrestin-1 and hb-arrestin-2 were designed based on Mission shRNA database (Sigma-Aldrich). Sequences for shRNAs were inserted into the pLKO-EGFP-IRES-puro vector. H295R cells were infected with the viruses in the presence of polybrene (8 mg ml À1 ) for 18 hr and then the medium was renewed. After 5 days, the medium was removed and ligands in serum-free medium were added to the well followed by 24 hr of incubation at 37 C.
Statistical Analyses
Results are expressed as the mean ± SEM. Differences between two groups were assessed by unpaired two-tailed t tests. Data involving multiple groups were assessed by ANOVA.
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